Peer-Reviewed Publication
Diagnostics (Basel)2024;14(16)August 21, 2024Journal Article

Polygenic Risk Score (PRS) Combined with NGS Panel Testing Increases Accuracy in Hereditary Breast Cancer Risk Estimation.

Nikolaos Tsoulos1, Eirini Papadopoulou1, Konstantinos Agiannitopoulos1, Dimitrios Grigoriadis1, Georgios N Tsaousis1, Dimitra Bouzarelou1, Helen Gogas2, Theodore Troupis3, Vassileios Venizelos4, Elena Fountzilas5, Maria Theochari6, Dimitrios C Ziogas2, Stylianos Giassas7, Anna Koumarianou8, Athina Christopoulou9, George Busby10, George Nasioulas1, Christos Markopoulos3
1Genekor Medical S.A., 15344 Athens, Greece.
2First Department of Internal Medicine, Laikon General Hospital, School of Medicine, National Kapodistrian University of Athens, 11527 Athens, Greece.
3School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
4Metropolitan Hospital, 18547 Athens, Greece.
5Second Department of Medical Oncology, Euromedica General Clinic, 54645 Thessaloniki, Greece.
6Oncology Unit, "Hippokrateion" General Hospital of Athens, 11527 Athens, Greece.
7Second Oncology Clinic IASO, General Maternity and Gynecology Clinic, 15123 Athens, Greece.
8Hematology Oncology Unit, 4th Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece.
9Oncology Unit, ST Andrews General Hospital of Patras, 26332 Patras, Greece.
10Allelica Inc., 447 Broadway, New York, NY 10013, USA.

Abstract

Breast cancer (BC) is the most prominent tumor type among women, accounting for 32% of newly diagnosed cancer cases. BC risk factors include inherited germline pathogenic gene variants and family history of disease. However, the etiology of the disease remains occult in most cases. Therefore, in the absence of high-risk factors, a polygenic basis has been suggested to contribute to susceptibility.…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.